NCT06984250
Hypofractionated Radiotherapy With Concomitant Tumor Bed Boost for Breast Cancer
Recruiting · Not specified · National Taiwan University Hospital · registry updated 2025-05-22
Inclusion and exclusion lines below are quoted from ClinicalTrials.gov. No match score is shown, because a score needs a person's age, biomarkers, and treatment dates. Confirm the record with the study team.
Hypofractionated breast radiotherapy with concomitant tumor bed boost for early breast cancer or ductal breast carcinoma in situ after partial mastectomy
Inclusion
- Female patients with histologically confirmed early-stage breast cancer (T1-2 and N0-1) or ductal carcinoma in situ (DCIS).
- Patients undergoing breast-conserving surgery
- Age ≥ 20 years
- Karnofsky Performance Status (KPS) ≥70%
- Life expectancy ≥ 5 years
- Adequate renal and hepatic function
Exclusion
- Pregnant patients
- Patients requiring re-irradiation of the thoracic region